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Abstract
Background
HCV GT4 accounts for up to 20% of HCV infections worldwide. Simeprevir, given for 12
weeks as part of a 24- or 48-week combination regimen with PR is approved for the treat-
ment of chronic HCV GT4 infection. Primary study objectives were assessment of efficacy
and safety of simeprevir plus PR in treatment-nawve patients with HCV GT4 treated for 12
weeks. Primary efficacy outcome was sustained virologic response 12 weeks post-treat-
ment (SVR12). Additional objectives included investigation of potential associations of rapid
virologic response and baseline factors with SVR12.
Methods
This multicentre, open-label, single-arm study (NCT01846832) evaluated efficacy and
safety of simeprevir plus PR in 67 patients with HCV GT4 infection. Patients were treat-
ment-nawve, aged 18–70 years with METAVIR F0–F2 fibrosis. Patients with early virologic
response (HCV RNA 25 IU/mL [detectable/undetectable in IL28B CC patients or undetect-
able in IL28B CT/TT patients] at Week 2 and undetectable at Weeks 4 and 8) were eligible
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to stop all treatment at the end of Week 12, otherwise PR therapy was continued to Week
24.
Results
Of 67 patients treated, 34 (51%) qualified for 12-week treatment including all but one patient
with IL28B CC genotype (14/15). All patients in the 12-week group had undetectable HCV
RNA at end of treatment, and 97% (33/34) achieved SVR12. No new safety signals with
simeprevir plus PR were identified. The proportion of patients experiencing Grade 3–4
adverse events was lower in the 12-week group than in the 24-week group.
Conclusions
Our findings on simeprevir plus PR therapy shortened to 12 weeks in patients with HCV
GT4 infection with favourable baseline characteristics and displaying early on-treatment
virologic response are encouraging. No new safety signals were associated with simeprevir
plus PR in this study.
Trial Registration
NCT01846832
Introduction
Hepatitis C virus (HCV) is among the leading causes of liver disease, estimated to affect
around 180 million people worldwide [1]. Untreated HCV infection puts patients at risk of
developing cirrhosis and hepatocellular carcinoma. Fortunately, cure of HCV infection is now
possible in most cases [2]. Sustained virologic response (SVR), defined as undetectable HCV
RNA 12 weeks after end of treatment (SVR12), is associated with cure of the infection in
>99% of patients and is the primary measure of efficacy of HCV treatment [1].
HCV variants are classified into seven genotypes whose coding region sequences differ by at
least 15% [3]. HCV treatment efficacy varies according to HCV genotype [4]. HCV genotype 4
(GT4) has not, until recently, been the focus of the same extent of research as GT1–3, although
GT4 is responsible for approximately 34 million HCV infections worldwide, and represents up
to 20% of all cases [5]. GT4 is particularly widespread in the Middle East and sub-Saharan
Africa, where it accounts for over 80% of cases [6, 7]. It is becoming increasingly prevalent in
Southern Europe, as a result of migration and spread of the virus through injection drug users
[7, 8].
HCV GT4 has long been considered to be one of the more difficult genotypes to treat, since
peginterferon-ċ (IFN; P) and ribavirin (RBV; R))-only regimens are only partially effective in
patients with HCV GT4 [9, 10]. Historically, treatment of HCV GT4 with PR necessitated a
48-week treatment regimen and achieved SVR rates of 43–70% [10].
The advent of IFN-free DAA regimens has revolutionised HCV treatment. SVR rates
exceeding 90% have been achieved across all genotypes, even in treatment-experienced
patients and those with advanced fibrosis, in randomised trials and real-world studies. Regi-
mens demonstrating effectiveness in GT4 with 8 or 12 weeks of treatment include ombitasvir/
paritaprevir/ritonavir (OBV/PTV/r) [11–15], simeprevir plus sofosbuvir [16], elbasvir plus
grazoprevir [17], and sofosbuvir plus ledipasvir [18]. Furthermore, pan-genotypic DAA
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therapies such as velpatasvir, which has recently demonstrated an SVR12 rate approaching
100% when administered for 12 weeks in combination with sofosbuvir [19], have the potential
to eliminate the need for genotyping and thereby greatly simplify treatment. GS-9857 [20, 21]
and ravidasvir [22] also show significant promise in this area; the latter has demonstrated a
97% SVR12 rate in 182 non-cirrhotic patients with HCV GT4 in Egypt when given for 12
weeks in combination with sofosbuvir [23].
However, the cost of DAAs and restricted availability remain significant barriers to
access to treatment for many HCV patients even in the most developed countries [24].
These barriers are particularly formidable for regimens containing two or more DAAs.
Even in 2016, access to IFN-free regimens continues to be restricted to patients with
advanced liver disease (F3–F4 fibrosis) and/or those who cannot tolerate IFN in many
European and Asian countries [25, 26]. Single-DAA IFN-based regimens may broaden the
range of patients able to access effective treatment earlier in the disease course, forestalling
the progress of liver disease, decreasing the risk of hepatocellular carcinoma, and increas-
ing the likelihood of success with short-course treatment. The clinical management and
adverse event burdens associated with PR therapy [27] mean that decreasing treatment
duration is very appealing to patients and physicians.
Simeprevir is a once-daily DAA approved for use in combination with PR or with sofosbu-
vir in HCV GT1 and GT4 [28, 29]. Simeprevir plus PR has demonstrated SVR rates of 83% in
treatment-naïve patients and 86% in prior relapsers with GT4 following 12 weeks of simeprevir
plus 24–48 weeks of PR [30].
Previous findings suggest that the overall duration of IFN-based therapy in combination
with a protease inhibitor could be shortened to 12 weeks in some patients without reducing its
efficacy [31]. In patients infected with HCV GT1 and F0–F2 fibrosis only, SVR12 rates of
>80% were reported in patients with IL28BCC genotype (94%) or HCV RNA800,000 IU/
mL (82%) who received simeprevir plus PR for 12 weeks after achieving early on-treatment
response [32]. Recent reports suggest that timely initiation of therapy in patients with early-
stage fibrosis could be associated with improved long-term outcomes and reduced HCV-asso-
ciated mortality [33]. The analysis described here was conducted to assess the potential for
shortening the total duration of simeprevir plus PR treatment to 12 weeks in treatment-naïve
patients with HCV GT4 and F0–F2 fibrosis displaying an early on-treatment virologic
response.
Materials and Methods
Patients and study design
Amulticentre, open-label, single-arm, phase III clinical trial evaluating efficacy and safety of
simeprevir plus PR in treatment-naïve patients with HCV GT1 (reported separately [32]) and
GT4 infection took place between 3 September 2013 (first patient screened) and 31 August
2015 (date of last patient contact). The study was approved by each centre’s institutional review
board and conducted in accordance with the Declaration of Helsinki and Good Clinical Prac-
tice guidelines. The review boards are listed in S1 Text. Here we report data in the GT4
population.
Patients with HCV GT4 were recruited from centres in Austria, Belgium, France, Italy,
Saudi Arabia and Spain. Written informed consent was obtained from all patients at screening
prior to the performance of any study-specific assessments or procedures. Each patient
received an identification code to permit easy identification of each patient during and after
the study. The code list was treated as confidential and filed by the investigator in the study
file.
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Eligible patients were treatment-naïve adults aged 18 to 70 years with chronic HCV GT4
infection confirmed at least 6 months prior to screening, plasma HCV RNA>10,000 IU/mL,
and mild-to-moderate liver fibrosis (METAVIR F0–F2). HCV genotype subtype is based on
the NS5B assay or, if data were unavailable, on LIPA HCV II or TRUGENE results. Liver fibro-
sis score was confirmed by liver biopsy within 2 years of screening or non-invasive assessment
of liver disease stage by transient elastography performed within 6 months of screening [34].
For patients with liver biopsy data, lesions were evaluated according to the METAVIR scoring
system whereby fibrosis was staged on a 0–4 scale (F0: no fibrosis; F1: portal fibrosis without
septa; F2: few septa; F3: numerous septa without cirrhosis; F4: cirrhosis) [34, 35]. For non-
invasive fibrosis assessment, the following cut-offs were defined: FibroScan™ F0–F1<6.9 kPa,
F2<8 kPa [36, 37]; magnetic resonance elastography F0–F1<2.5 kPa; F2<3.1 kPa [38]. For
other methods, such as shear wave elastography, the advice of the sponsor was taken.
Exclusion criteria included advanced liver disease (METAVIR F3–F4) or liver disease of
aetiology other than HCV; previous or current hepatic decompensation; co-infection with
hepatitis B virus or HIV; significant abnormalities in laboratory parameters; pregnancy,
breast-feeding, or plans to conceive within 6 months of end of treatment.
Patients received simeprevir (150 mg once-daily, orally) in combination with peg-IFN alfa-
2a (180 μg, weekly by subcutaneous injection) and RBV (1000 mg/day if body weight<75 kg,
or 1200 mg/day if>75 kg, orally) [Simeprevir SmPC]. Total treatment duration was determined
on the basis of on-treatment response, with HCV RNA levels determined by Roche Cobas1
TaqMan v2.01 assay [lower limit of quantification 25 IU/mL; limit of detection 15 IU/mL].
Treatments were stored and administered by participants in accordance with instructions pro-
vided by study site personnel. The investigator or designated study site personnel maintained a
log of all study treatments dispensed and returned for compliance assessment purposes.
To be eligible for the 12-week regimen, patients were required to display HCV RNA<25
IU/mL at Week 2 (detectable or undetectable in patients with IL28BCC genotype, undetect-
able in those with CT or TT genotype), and undetectable HCV RNA at Weeks 4 and 8. For all
patients, the planned duration of simeprevir treatment was 12 weeks. Patients fulfilling the
12-week eligibility criteria also discontinued PR at Week 12; otherwise, PR treatment was con-
tinued for another 12 weeks following discontinuation of simeprevir (S1 Fig). Patients who
stopped treatment prior to Week 8 were assigned to the 24-week treatment group for the pur-
pose of the analysis.
Patients discontinued all treatment if they met any of the following virologic stopping rules:
HCV RNA concentration 25 IU/mL at Week 4; HCV RNA<25 IU/mL detectable or 25
IU/mL at Week 12; or viral breakthrough (defined as a confirmed increase of>1 log10 IU/mL
in HCV RNA concentration from the lowest level reached, or a confirmed HCV RNA level of
>100 IU/mL in patients whose HCV RNA level had previously been<25 IU/mL [detectable
or undetectable] while on study treatment).
Objectives
The objectives of the present study were to determine the efficacy, defined in terms of the pro-
portion of patients achieving SVR12, and the safety and tolerability of simeprevir plus PR in
patients with HCV GT4 eligible for the shortened (12-week) treatment regimen. SVR12 was
defined as HCV RNA<25 IU/mL undetectable 12 weeks after the planned end of all study
treatment. SVR12 is considered equivalent to SVR 24 weeks after end of treatment (SVR24).
Efficacy and safety of simeprevir plus PR in patients with HCV GT4 receiving 24 weeks of
treatment were also assessed, as were early virologic responses at Weeks 2 and 4, SVR24, and
on-treatment HCV RNA levels.
Simeprevir + PR 12-Week Regimen in HCV GT4
PLOS ONE | DOI:10.1371/journal.pone.0168713 January 5, 2017 4 / 16
Evaluations
Blood samples for determination of HCV RNA levels were collected at screening and/or base-
line, at each on-treatment study visit (Weeks 2, 4, 8, 12, 16, 20 and 24), and at the follow-up
visits (Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 36, and 48), as pre-specified in the time and events
schedule, or at the time of discontinuation of treatment. Genotyping of the rs12979860 single
nucleotide polymorphism of IL28B, previously shown to be strongly associated with SVR in
patients with HCV GT4 [9], was conducted at screening. Adverse events (AEs), as reported by
the patient or appropriate caregiver, were recorded throughout the study. Descriptions of AEs
were coded using the Medical Dictionary for Regulatory Activities. All reported AEs occurring
during the treatment phase were included in the safety analysis, in which the percentage of
patients experiencing each recorded AE was summarised according to treatment group.
Blood samples collected at each study visit were used for biochemical and haematological
analyses. Electrocardiograms, vital sign assessments and physical examinations were also per-
formed throughout the study period.
Statistical methods
The efficacy analysis population was the intent-to-treat (ITT) population, consisting of all study
participants with HCV GT4 who received at least one dose of study medication. Summary sta-
tistics for the effects of treatment and of viral clearance are reported for each treatment group.
Baseline factors associated with treatment cessation and eligibility for 12 weeks were also exam-
ined. Statistical analysis was conducted using SAS statistical analysis software (SAS Institute
Inc.). P-values for assessment of differences in demographic characteristics and adverse event
incidences between 12- and 24-week groups were calculated using the Chi-squared test (cate-
gorical parameters) or Wilcoxon-Mann-Whitney test (continuous parameters).
Results
Patient characteristics and disposition
The ITT population comprised 67 patients with HCV GT4 who received study treatment. The
majority of patients were male (69%) and white (80%), with 75% located in Europe, and the
remaining 25% being based in Saudi Arabia (Table 1). Most patients were infected with either
HCV GT4a (40%) or GT4d (37%) (S1 Table). Patients mainly had mild fibrosis (F0–F1, 81%),
and 22% had IL28BCC genotype.
Of the 67 GT4 patients enrolled in the study, 34 (51%) met the criteria for 12-week treat-
ment with all 34 completing 12 weeks of simeprevir plus PR (Fig 1).
Median body mass index was significantly greater (Wilcoxon-Mann-Whitney p = 0.01) in
the 24-week group than in the 12-week group. Patients in the 24-week group also had signifi-
cantly higher median HCV RNA levels (Wilcoxon-Mann-Whitney p = 0.011) and were more
likely to have non-CC IL28B genotype (Chi-Squared p = 0.00065) than those in the 12-week
group. All other patient characteristics assessed (Table 1) were not significantly different
between the two groups.
Of the 33 patients who were not eligible for the 12-week regimen and were therefore assigned
to receive 24 weeks of treatment, 28 (85%) completed simeprevir and 24 (73%) completed all
study therapy. Five patients in the 24-week group discontinued simeprevir: two met a virologic
stopping rule, and three discontinued treatment because of an AE. Two of these discontinua-
tions were considered not related to simeprevir; the other patient had AEs considered to be
probably related to simeprevir (erythema [Grade 1] and pruritus [Grade 2]). Nine patients in
the 24-week group discontinued PR: five as described above, who also discontinued simeprevir,
Simeprevir + PR 12-Week Regimen in HCV GT4
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one patient who discontinued PR only [due to erythema nodosum]) and three because of non-
compliance (Fig 1). All patients who discontinued PR were in the PR-only treatment phase; no
patients received simeprevir monotherapy.
Eligibility of patients for 12 weeks total treatment duration
Patients with IL28BCC genotype appeared more likely to stop all treatment at Week 12 (93%
of IL28BCC patients compared with 36% of CT and 50% of TT patients); the difference in
response guided therapy criteria for IL28BCC versus non-CC patients did not explain this
observation, since 12/14 of IL28BCC patients in the 12-week group had undetectable HCV
Table 1. Patient Demographics and Disease Characteristics at Baseline for Patients with HCV GT4 by Treatment Duration and Overall (n = 67).
duration
12 weeks (n = 34) 24 weeks (n = 33) All patients (N = 67)
Male, n (%) 23 (68) 23 (70) 46 (69)
Median age (range), years 47.5 (19–63) 48 (21–66) 48 (19–66)
Race, n/N (%)*
White 23/30 (77) 24/29 (83) 47/59 (80)
Black or African American 3/30 (10) 4/29 (14) 7/59 (12)
Asian 2/30 (7) 1/29 (3) 3/59 (5)
Multiple 2/30 (7) 0 2/59 (3)
Geographical region, n/N (%)
Europe 24 (71) 26 (79) 50 (75)
Saudi Arabia 10 (29) 7 (21) 17 (25)
Body mass index, kg/m2, median (interquartile range) 24.6 (22.1, 27.5) 27.5 (24.8, 30.4) 26.3 (23.0, 29.6)
HCV genotype subtype†, n (%)
4 1 (3) 1 (3) 2 (3)
4a 14 (41) 13 (39) 27 (40)
4a/4c/4d 1 (3) 1 (3) 2 (3)
4c 1 (3) 1 (3) 2 (3)
4d 13 (38) 12 (36) 25 (37)
Other 4 subtypes‡ 4 (12) 5 (15) 9 (13)
Baseline HCV RNA, log10 IU/mL, median (range) 5.8 (3.1–7.5) 6.4 (4.8–7.2) 6.1 (3.1–7.5)
Baseline HCV RNA, IU/mL, n (%)
400,000 11 (32) 3 (9) 14 (21)
 400,000 –800,000 8 (24) 4 (12) 12 (18)
!800,000 15 (44) 26 (79) 41 (61)
METAVIR score, n (%)
F0–F1 29 (85) 25 (76) 54 (81)
F2 5 (15) 7 (21) 12 (18)
F3 – 1 (3) 1 (1)
IL28B genotype subtype, n (%)
CC 14 (41) 1 (3) 15 (22)
CT 15 (44) 27 (82) 42 (63)
TT 5 (15) 5 (15) 10 (15)
GT4, genotype 4; HCV, hepatitis C virus.
*Race data unavailable for 8 patients: not allowed to ask per local regulations.
†HCV genotype subtype is based on the NS5B assay, and if not available on LIPA HCV II or Trugene results.
‡Other subtypes were 4e, 4f, 4k, 4n, 4q and 4r.
doi:10.1371/journal.pone.0168713.t001
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Fig 1. Patient Disposition Flow Chart for Patients with HCV GT4.
doi:10.1371/journal.pone.0168713.g001
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RNA at Week 2. A greater proportion of patients with low RNA viral load at baseline were eli-
gible for the 12-week group–respectively, 79% of patients with HCV RNA< 400,000 IU/mL,
67% of patients with HCV RNA 400,000–800,000 IU/mL, and 37% of patients with HCV
RNA> 800,000 IU/ml qualified to stop treatment at Week 12. There were small or no differ-
ences in 12-week eligibility rates according to gender, HCV 4 subtype, race, geographical
region, or fibrosis stage on eligibility for 12 weeks versus 24 weeks of treatment (Fig 2;
Table 1). The minimal dataset of the present study is available in S1 Dataset.
Efficacy
Among all patients with GT4 receiving 12 or 24 weeks of simeprevir plus PR, 90% (60/67)
achieved SVR12.
All patients with GT4 receiving the 12-week treatment regimen had undetectable HCV
RNA at end of treatment; 97% (33/34) achieved SVR12 (Fig 3) and SVR24 (Data Not Shown).
The one patient in the 12-week group who did not achieve SVR12 relapsed 58 days after the
end of treatment. This patient was male, infected with HCV GT4d, had IL28BCC genotype,
F0–F1 fibrosis and had a baseline HCV RNA of 2,080,000 IU/mL.
Among those GT4 patients assigned to the 24-week treatment group, 82% (27/33) achieved
SVR12 and SVR24. Three patients experienced on-treatment failure: two met the Week 4 stop-
ping rule (HCV RNA 25 IU/mL at Week 4) and one discontinued all study drugs during the
first week of therapy due to pyrexia, oropharyngeal pain, headache and abdominal pain, and
had detectable HCV RNA at time of discontinuation.
Three patients in the 24-week group experienced relapse post-treatment (two completed
PR and one stopped all treatment at Week 8 due to depression) (S2 Table). The two patients
who had completed the 24 weeks of treatment relapsed between follow-up Weeks 4 and 12.
Fig 2. Eligibility for 12-week simeprevir plus PR regimen according to patient baseline characteristics.
doi:10.1371/journal.pone.0168713.g002
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The patient who discontinued prematurely due to depression relapsed during the first 4 weeks
of follow up. All had IL28B non-CC genotype.
Safety
Among all GT4 patients included in the analysis (n = 67), 60 (90%) experienced at least one
treatment-emergent AE. The most commonly reported treatment-emergent AEs (reported in
 20% of patients in either treatment group) were pruritus, neutropenia, asthenia, fatigue,
decreased appetite, influenza-like illness and headache (Table 2). Two patients (3%)
Fig 3. SVR12 among patients with HCV GT4 in the 12-week treatment group.
doi:10.1371/journal.pone.0168713.g003
Table 2. On-treatment AEs Reported During the Study Period.
Treatment duration All patients
12 weeks (n = 34) 24 weeks (n = 33) All patients (N = 67)
Any AE 31 (91) 29 (88) 60 (90)
Any serious AE 0 2 (6) 2 (3)
Any AE at least possibly related to simeprevir 10 (29) 15 (45) 25 (37)
Any AE at least possibly related to peg-IFN 20 (59) 26 (79) 46 (69)
Any AE at least possibly related to RBV 17 (50) 19 (58) 36 (54)
Any AE leading to permanent stop of all study drugs 0 3 (9) 3 (4)
Worst Grade 3 or 4 AE* 6 (18) 14 (42) 20 (30)
Most commonly reported AE†
Pruritus 9 (26) 7 (21) 16 (24)
Neutropenia 9 (26) 7 (21) 16 (24)
Asthenia 5 (15) 9 (27) 14 (21)
Fatigue 6 (18) 8 (24) 14 (21)
Decreased appetite 6 (18) 8 (24) 14 (21)
Headache 5 (15) 8 (24) 13 (19)
Influenza-like illness 3 (9) 9 (27) 12 (18)
AE, adverse event; peg-IFN, pegylated interferon; RBV, ribavirin.
*Three Grade 3 AEs were considered at least possibly related to simeprevir: asthenia (n = 2) and blood bilirubin increase (n = 1), all in the 24-week group.
No Grade 4 AEs were considered at least possibly related to simeprevir.
†Occurring in 20% of patients in either treatment group.
doi:10.1371/journal.pone.0168713.t002
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experienced a serious AE (acute sinusitis [n = 1] and phlebitis [n = 1]); both occurred in
patients in the 24-week group and were considered not to be related to simeprevir (Table 2).
Four patients discontinued at least one study treatment (PR ± simeprevir) because of AEs.
All four were in the 24-week group. Only one (erythema and pruritus [n = 1]), was considered
probably related to simeprevir (the patient discontinued all treatment during Weeks 10–11).
The other three (depression [n = 1, discontinued all treatment at Week 8], pyrexia/oropharyn-
geal pain/headache/abdominal pain [n = 1, discontinued all treatment during Week 1], and
erythema nodosum [n = 1, discontinued PR during Weeks 22–23]) were considered not to be
related to simeprevir.
Similar proportions of patients in the 12- and 24-week groups (91% and 88% respectively;
Chi-Squared p = NS) reported treatment-emergent AEs (all grades) and AEs of special interest.
Overall, a higher proportion of patients experienced Grade 3/4 AEs in the 24-week group
(42% [14/33]) than the 12-week group (18% [6/34]; Chi-Squared p = 0.027). However, of the
Grade 3/4 AEs experienced by patients in the 24-week group, 11 had their onset in the first 12
weeks of treatment and four began during the PR-only phase. Of those patients who received
at least one dose of PR in the PR-only phase, 18/27 (67%) experienced 1 new AE during
Weeks 12–24 and 4/27 (15%) experienced a worst Grade 3/4 AE during this phase.
Most on-treatment Grade 3/4 AEs, across both groups, were not considered related to sime-
previr (85% [17/20]). The three Grade 3/4 AEs considered at least possibly related to simepre-
vir were Grade 3 instances of asthenia [n = 2] and increased blood bilirubin [n = 1], all in the
24-week group. Grade 4 AEs were reported in three patients in the 24-week group (neutrophil
count decrease [n = 3]) and none in the 12-week group; all Grade 4 AEs were considered not
to be related to simeprevir.
Most on-treatment Grade 3/4 AEs were considered related to peg-IFN (90% [18/20]) and
some were also considered related to RBV (30% [6/20]); however, all Grade 4 AEs were consid-
ered not to be related to RBV (S3 Table).
Regardless of AE severity or causality, the proportions of patients in whom asthenia (27%
versus 15%), fatigue (24% versus 18%) and influenza-like illness (27% versus 9%) were
observed were markedly higher in the 24-week arm than the 12-week arm.
Findings of the laboratory analysis of haemoglobin, neutrophils and precursors, platelets,
and bilirubin are summarised in S2 Fig.
Discussion
This study comprised 67 treatment-naïve patients with HCV GT4 mild-to-moderate (F0–F2)
fibrosis, infected with various GT4 subtypes (GT4a, d or others). The overall SVR12 rate for
patients who met the eligibility criteria for the 12-week group and discontinued both simepre-
vir and PR after 12 weeks of treatment was 97% (33/34). All patients who achieved SVR12 also
achieved SVR24. The 34 patients who discontinued all treatment at Week 12 represented 51%
of the total GT4 patient population.
The simeprevir plus PR regimen has previously displayed an acceptable safety and tolerabil-
ity profile in patients with HCV GT1 [39] and GT4 [30]. No new safety signals were identified
in this study. The same proportion of patients in the 12- and 24-week groups reported any AE.
However, 67% of patients in the 24-week group who received PR experienced at least one new
AE during the PR-only phase, and four patients experienced a new Grade 3/4 AE during this
phase. Ending treatment after 12 weeks appeared to be associated with a reduction in overall
treatment-associated morbidity versus the 24-week or longer regimen. Notably, the majority
of Grade 3, and all Grade 4 AEs were considered unrelated to simeprevir, whereas 90% of
Grade 3/4 AEs were considered related to peg-IFN.
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Excellent results have been reported in broad HCV patient populations, including treat-
ment-naïve and -experienced patients with HCV GT4, with a variety of IFN-free combination
DAA regimens [11–23]. SVR rates exceeding 95% are now routinely reported in randomised
clinical trials and in real-world studies after 12 weeks of treatment with such combinations.
However, access to treatment continues to be limited by availability and cost, and the propor-
tion of patients who can receive such regimens, if any, varies widely across countries and
socioeconomic groups [25, 26, 40]. Voluntary licensing agreements have dramatically
improved access to IFN-free regimens such as sofosbuvir plus ledipasvir in some countries,
such as Egypt, but prices remain unaffordably high in many others [41] and are likely to
remain so for some time in the absence of agreements [42]. Efforts are ongoing to improve
access more widely (e.g. [43]); however as of 2016 there remains a sizable patient population
who would clearly benefit from DAA therapy but are untreated or receiving clearly inferior
regimens. For instance, in Greece–which has one of the highest rates of HCV prevalence in
Europe with 14% of patients having GT4 –PR-only regimens remain widely used with esti-
mated SVR of just 65% following 48 weeks of treatment [44].
In accordance with clinical practice recommendations, patients with advanced fibrosis or
cirrhosis are typically prioritised for treatment [1, 26]. In many middle- and even high-income
countries, patients with F0–F2 fibrosis continue to be ineligible for treatment [25, 26]. In Italy,
the country with the highest HCV prevalence in Europe, simeprevir is the only DAA eligible
for reimbursement for treatment of patients with F0–F2 fibrosis; other European countries do
not reimburse DAA therapy at all for this patient population [45]. The cost-effectiveness of
early treatment is well established [46–48], particularly when the risks of transmission and of
complications such as hepatocellular carcinoma are taken into consideration [49–52]. Indeed,
broadening access to treatment and eliminating the requirement for fibrosis staging to deter-
mine eligibility may be essential if future HCV incidence is to be significantly reduced [53].
Our findings are similar to those previously reported with an IFN-based single-DAA regi-
men in a similar, though smaller, treatment-naïve GT4 patient population [54]: an SVR rate of
96% (27/28) was achieved with 12 weeks of sofosbuvir plus PR. IFN-free single-DAA regimens
of sofosbuvir plus RBV have been assessed in two studies of GT4 patients in Egypt and of
Egyptian ancestry [55, 56], with overall SVR rates after 12 weeks of treatment of 77% and 68%,
respectively (84% and 79% in treatment-naïve patients); SVR rates of 90% were achieved in
both studies with 24 weeks of sofosbuvir plus PR.
HCV genotype 4 is particularly heterogeneous, with more described subtypes than for any
other genotype [3]. In the aforementioned study of patients of Egyptian ancestry, SVR rates
approaching 100% were achieved with 12 weeks of sofosbuvir plus PR in treatment-naïve
patients with low (<600,000 IU/mL) baseline viral load and F0–F2 fibrosis [56]. In the
RESTORE study of simeprevir plus PR [30], 94% (29/31) of treatment-naïve patients meeting
response-guided therapy criteria achieved SVR12 with 12 weeks of simeprevir plus PR fol-
lowed by 12 weeks of PR.
The criteria we used to determine eligibility to shorten total treatment duration of simepre-
vir plus PR treatment to 12 weeks were informed by previous observations of increased likeli-
hood of SVR in patients displaying an early on-treatment virologic response [30, 54, 57, 58].
Based on previous findings of markedly greater treatment efficacy in HCV GT1-infected
patients with IL28BCC genotype, more stringent eligibility criteria for 12-week treatment
were applied to non-CC patients [32]. Virologic response was the only on-treatment factor
used to determine eligibility for 12-week treatment. Among IL28BCC patients, 93% were eligi-
ble to stop therapy at Week 12 compared with 38% of IL28B non-CC, and all but one IL28B
CC patient achieved SVR12. A low baseline viral load appeared to increase the probability of
eligibility to stop all therapy at Week 12. No apparent effects of GT4 subtype, race, sex,
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geographical region or fibrosis stage on likelihood of eligibility for shortened treatment were
observed and very high SVR rates were noted regardless of baseline characteristics. This is in
accordance with previous findings with IFN-containing regimens, showing that early on-treat-
ment response is associated with high SVR rates. Early on-treatment response continues to be
more informative about eventual outcomes than baseline characteristics even as overall treat-
ment duration is reduced to 12 weeks.
Examining negative baseline predictors of SVR in the 12-week group was not possible as
treatment was successful in all but one patient in this group. However, it is noteworthy that
patients infected with non-4a HCV genotypes treated for 12 weeks achieved 95% (19/20) SVR12
in this study. Genotype subtype has previously appeared to play a role in treatment outcomes for
HCV GT4-infected patients treated with PR alone, with lower SVR rates observed in patients
infected with a non-4a HCV genotype [59]. Although the numbers are small in this study, GT4
subtype did not appear to influence SVR rates in patients receiving 12 weeks of therapy, as only
one such patient failed. This is particularly encouraging as the distribution of GT4 subtypes is
subject to substantial geographical variation, with many regions of Africa, such as the Demo-
cratic Republic of the Congo and Gabon having a high prevalence of GT4 non-4a subtypes [8].
The substantial benefits of early treatment, in the context of ongoing limitation of access to
DAAs in many countries in which HCV GT4 is prevalent, mean that an option of a short-
duration, single-DAA, IFN-based regimen remains of considerable potential interest. PR treat-
ment has previously been determined to be cost-effective even when non-drug costs associated
with treatment, such as genotyping and clinical management, are taken into account [60].
However, the on-treatment impact on quality of life of protracted PR-only regimens, com-
bined with their relatively low success rates even in patients with mild fibrosis, represent a con-
siderable disincentive for patients to embark upon and adhere to HCV treatment [27].
The patients with HCVGT4 who participated in this study were recruited at sites in Europe
and Saudi Arabia. The sample was well-balanced in terms of GT4 subtype and IL28B genotype
and is considered to be representative of GT4 patients in Europe and the Middle East; subtype 4a
and the IL28BCC genotype are relatively uncommon in sub-Saharan Africa [32], and the study
population may, therefore, be less representative of sub-Saharan African patients. The sample size
of 67 was similar to those of previously-reported DAA studies in HCVGT4, but we urge caution
when interpreting the subgroup data because of the small numbers. Additionally, the eligibility
criteria were defined such that patients who were not eligible for shortened treatment (e.g. because
they discontinued treatment because of an AE or experienced virologic failure) were included by
default in the 24-week group, potentially impacting the interpretation of the SVR data.
In conclusion, simeprevir plus PR for a total treatment duration of 12 weeks in treatment-
naïve patients with early virologic response and mild to moderate liver fibrosis (METAVIR
F0–F2) demonstrated an encouragingly high SVR rate.
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